Atrial Fibrillation
Conditions
Interventions
Cardiovascular disease patients with atrial fibrillation:No intervention
Cardiovascular disease patients without atrial fibrillation:No intervention
Patients with simple paroxysmal atrial fibrillation:No intervention
Sponsors
Department of Cardiovascular Surgery, General Hospital of Northern Theater Command
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Healthy volunteers participating in this trial must meet all the following criteria: 1.Age: 18 = age = 80 years old; 2.No history of cardiovascular diseases (such as hypertension, coronary heart disease, arrhythmia, etc.). 3.No other major chronic diseases (such as diabetes, chronic kidney disease, liver disease, etc.). 4.No acute or chronic infectious diseases. 5.No history of major surgery or trauma in the recent past (within the last 6 months). 6.Electrocardiogram examination: Normal baseline 12 - lead electrocardiogram, without evidence of atrial fibrillation or other arrhythmias. 7.Laboratory tests: Blood routine, liver and kidney function, blood lipids, blood glucose and other indicators are within the normal range. No significant abnormalities in inflammatory markers (such as C - reactive protein, erythrocyte sedimentation rate, etc.). 8.Good compliance and able to cooperate to complete the PET imaging. Patients participating in this trial must meet all the following criteria: 1.Age: 18 = age = 80 years old; 2.Clear clinical diagnosis: including rheumatic heart disease, coronary atherosclerotic heart disease, hypertrophic obstructive cardiomyopathy, hypertensive heart disease, simple paroxysmal atrial fibrillation, simple persistent atrial fibrillation; 3.Undergo routine cardiac surgery or cardiac department atrial fibrillation ablation treatment. 4.Good compliance and able to cooperate to complete the PET imaging.
Exclusion criteria
Exclusion criteria: Research participants should not participate in this trial if any of the following situations apply: 1. Aged > 80 years; 2. Allergic constitution; 3. Claustrophobia; 4. Emergency surgery; 5. Congenital heart disease; 6. Impairment of liver and kidney function (test results exceed 3 times the upper limit of the normal value); 7. Diseases requiring radiotherapy, chemotherapy, or long-term hormone treatment; 8. Poorly controlled hyperthyroidism; 9. Participation in another clinical trial; 10. Refusal to enroll.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FAPI opacification; | — |
Secondary
| Measure | Time frame |
|---|---|
| atrial fibrillation burden;Ventricular rate during AF;Days of hospital stay following surgery;Inflammatory makers;Actionable AF: antiarrhythmic use (including rate-control meds), CDV, anticoagulation, use of inotropes for BP support during AF;Duration of blocking time and extracorporeal circulation;The incidence of Premature Atrial Contraction (PAC), Couplets and Nonsustained Atrial Tachyarrhythmia; | — |
Countries
China
Contacts
Public ContactHuishan Wang
Department of Cardiovascular Surgery, General Hospital of Northern Theater Command
Outcome results
None listed